by Madaline Spencer | Sep 3, 2025
The U.S. Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib) for the treatment of adults with persistent or chronic immune thrombocytopenia (ITP) who have had insufficient response to previous treatment. ITP is a rare bleeding disorder...
by Madaline Spencer | Sep 3, 2025
Margarita Ochoa-Maya, MD, Medical Director of the Rare Disease Business Unit at Amgen, discusses the TEDucation campaign for thyroid eye disease (TED). TED is a rare autoimmune disease that can dramatically impact a person’s vision. The condition often occurs...
by Madaline Spencer | Sep 3, 2025
Javier Oesterheld, MD, Division Chief of the Cancer and Blood Disorders Program at Levine Children’s Hospital and Founder and Executive Director of the ARISE Cancer Consortium, discusses naxitamab combination therapy for the treatment of patients with...
by Madaline Spencer | Sep 2, 2025
The U.S. Food and Drug Administration (FDA) has approved the updated Risk Evaluation and Mitigation Strategy (REMS) for Filspari (sparsentan) for the treatment of IgA nephropathy (IgAN). IgAN is a rare disorder that occurs when IgA accumulates in the kidneys. In the...
by Madaline Spencer | Sep 2, 2025
Robin Williams, MD, Pediatric Hematology Oncologist at M Health Fairview Masonic Children’s Hospital, discusses her experience diagnosing and treating a patient with Castleman disease (CD). CD is a rare condition that affects the lymph nodes and related...
